XM levert geen diensten aan inwoners van de Verenigde Staten.

XM levert geen diensten aan inwoners van de Verenigde Staten.
R
R

Roche

Nieuws

Reuters - 3 dagen geleden

Deutsche Bank upgrades "high growth unicorn" Eli Lilly to 'buy', raises PT

BUZZ-Deutsche Bank upgrades "high growth unicorn" Eli Lilly to 'buy', raises PT ** Brokerage Deutsche Bank upgrades Eli Lilly LLY.N to 'buy' from 'hold', raises PT to $1,025 from $725 ** Calls the drugmaker a "high growth unicorn", says big beat-and-raise quarter helped settle some nerves ** Says sales of its diabetes drug Mounjaro outside US will create a large revenue base and drive growth ** Lilly plans to launch 2.5 milligrams and 5 mg single-dose vials of its weight-loss drug, Zepbound, in
R
Reuters - 1 week geleden

Biotech firm Recursion to buy smaller peer Exscientia for $688 million

Biotech firm Recursion to buy smaller peer Exscientia for $688 million By Anirban Sen NEW YORK, Aug 8 (Reuters) - Recursion Pharmaceuticals RXRX.O , a biotech firm which uses artificial intelligence to discover new drug candidates, has agreed to buy smaller rival Exscientia EXAI.O for $688 million in an all-stock deal, according to a statement seen by Reuters.
B
N
R
S
Reuters - 1 week geleden

Europe's STOXX 600 jumps 1% on banks-led recovery; Novo Nordisk slumps

UPDATE 2-Europe's STOXX 600 jumps 1% on banks-led recovery; Novo Nordisk slumps For a Reuters live blog on U.S., UK and European stock markets, click LIVE/ or type LIVE/ in a news window Novo Nordisk logs steepest decline since Aug 2022 Puma slumps after narrowing FY profit outlook Continental up after Q2 results beat Just Eat Takeaway top STOXX 600 gainer after rating upgrade Roche considering divesting $1.9 bln cancer data startup- FT STOXX 600 up 1.5% Updated at 1550 GMT By Ankika Biswas and
B
C
J
P
R
A
E
F
S
U
G
Reuters - 1 week geleden

Green shoots for stocks

LIVE MARKETS-Green shoots for stocks Welcome to the home for real-time coverage of markets brought to you by Reuters reporters. You can share your thoughts with us at markets.research@thomsonreuters.com . GREEN SHOOTS FOR STOCKS European stocks are set for a positive start to Wednesday after jittery investors were reassured after The Bank of Japan's deputy governor played down the chance of a near-term interest rate hike.
H
L
R
E
F
G
Reuters - 1 week geleden

Swiss stocks - Factors to watch on August 7

Swiss stocks - Factors to watch on August 7 ZURICH/GDANSK, Aug 7(Reuters) - Here are some of the main factors that may affect Swiss stocks on Wednesday: COMPANY STATEMENTS ROCHE HOLDING ROG.S Roche considering divesting $1.9 bln cancer data startup, FT reports. LOGITECH INTERNATIONAL LOGN.S Matteo Anversa to join Logitech as CFO. ECONOMY Swiss July Forex Reserves due at 0700 GMT.
L
R
Reuters - 1 week geleden

Roche considering divesting $1.9 bln cancer data startup, FT reports

UPDATE 3-Roche considering divesting $1.9 bln cancer data startup, FT reports Adds details from FT report in paragraphs 4-5 and Citi response in paragraph 7 Aug 7 (Reuters) - Swiss pharmaceutical company Roche ROG.S is considering divesting cancer data specialist Flatiron Health, the Financial Times reported on Wednesday, citing people familiar with the matter.
C
G
R
Reuters - 1 week geleden

Roche considering divesting $1.9 bln cancer data startup, FT reports

Roche considering divesting $1.9 bln cancer data startup, FT reports Aug 7 (Reuters) - Swiss pharmaceutical company Roche ROG.S is considering divesting cancer data specialist Flatiron Health, the Financial Times reported on Wednesday, citing people familiar with the matter. Roche had paid $1.9 billion for New-York based Flatiron Health in 2018. Re
R
Reuters - 1 week geleden

Sangamo Therapeutics rises on licensing agreement with Genentech

BUZZ-Sangamo Therapeutics rises on licensing agreement with Genentech ** Shares of gene therapy developer Sangamo Therapeutics SGMO.O surge 60.83% to $1.23 ** Co says it has entered into a license agreement with Roche's ROG.S Genentech to develop therapies for neurodegenerative diseases ** Sangamo has granted Genentech an exclusive license to Sanga
R
Reuters - 2 weken geleden

Arkema, Man Group, Shell

EUROPE RESEARCH ROUNDUP- Arkema, Man Group, Shell Aug 2 (Reuters) - Securities analysts revised their ratings and price targets on several European companies including Arkema, Man Group and Shell, on Friday. HIGHLIGHTS * Arkema SA AKE.PA : HSBC raises target price to EUR 105 from EUR 103 * Berkeley Group BKGH.L : Jefferies raises target price to 4,936p from 4,834p * Diageo Plc DGE.L : Morgan Stanley cuts target price to 2200p from 2380p * Man Group Plc EMG.L : Peel Hunt cuts to add from buy * Sh
A
A
A
A
A
B
B
B
B
B
C
C
C
D
E
E
M
R
S
S
U
A
B
T
Reuters - 2 weken geleden

Regeneron beats quarterly results on strong demand for eczema, eye treatments

Regeneron beats quarterly results on strong demand for eczema, eye treatments Aug 1 (Reuters) - Drugmaker Regeneron Pharmaceuticals REGN.O exceeded estimates for second-quarter revenue and profit on Thursday, driven by strong demand for its top-selling eczema and eye drugs. The company has been upgrading patients who use its eye treatment, Eylea, to a higher-dose version to beat the impact from cheaper biosimilars available in the market and rival drugs.
B
R
R
S
Reuters - 2 weken geleden

BofA sees buying opportunity in Novo amid recent pullback

BUZZ-BofA sees buying opportunity in Novo amid recent pullback ** BofA Global Research sees "macroeconomic pullback" as a buying opportunity for investors in Novo Nordisk NOVOb.CO , confirming its "buy" rating on the obesity drugs maker ** It notes the Danish pharma giant's shares have fallen about 15% since highs in July , while it sees growth cat
R
Reuters - 2 weken geleden

European Commission Approves Roche’S Vabysmo For Treatment Of RVO

BRIEF-European Commission Approves Roche’S Vabysmo For Treatment Of RVO July 30 (Reuters) - ROCHE HOLDING AG ROG.S : EUROPEAN COMMISSION APPROVES ROCHE’S VABYSMO FOR TREATMENT OF RETINAL VEIN OCCLUSION (RVO) VABYSMO IS ALREADY APPROVED IN SEVERAL COUNTRIES, INCLUDING US AND JAPAN ADDITIONAL SUBMITTED DATA SHOWS THAT UP TO 60% OF PEOPLE RECEIVIN
R
Reuters - 2 weken geleden

Roche Holding AG Says Fast-Tracking Clinical Development Of Obesity Portfolio - Spokesperson

BRIEF-Roche Holding AG Says Fast-Tracking Clinical Development Of Obesity Portfolio - Spokesperson July 29 (Reuters) - Roche Holding AG ROG.S : ROCHE HOLDING AG - FAST-TRACKING CLINICAL DEVELOPMENT OF OBESITY PORTFOLIO - SPOKESPERSON ROCHE HOLDING AG - CT-996 WILL BE MOVING TOWARDS PHASE 2 TRIALS NEXT YEAR - SPOKESPERSON ROCHE HOLDING AG - AIM TO B
R
Reuters - 2 weken geleden

Roche Closes Acquisition Of Lumiradx’S Point Of Care Technology

BRIEF-Roche Closes Acquisition Of Lumiradx’S Point Of Care Technology July 29 (Reuters) - ROCHE HOLDING AG ROG.S : ROCHE CLOSES ACQUISITION OF LUMIRADX’S POINT OF CARE TECHNOLOGY TO EXPAND ACCESS TO DIAGNOSTIC TESTING IN PRIMARY CARE Source text for Eikon: ID:nGNEb5BzHp Further company coverage: ROG.S (Gdansk Newsroom)
R
Reuters - 2 weken geleden

Roche to fast-track weight loss drugs to compete with rivals, FT reports

UPDATE 1-Roche to fast-track weight loss drugs to compete with rivals, FT reports Adds details from FT report throughout; background in paragraphs 2 and 4 July 29 (Reuters) - Swiss drugmaker Roche ROG.S plans to accelerate the development of its anti-obesity drugs to challenge rivals like Eli Lilly LLY.N and Novo Nordisk NOVOb.CO in the booming market, the Financial Times reported on Monday.
R
Reuters - 2 weken geleden

Swiss stocks - Factors to watch on July 29

Swiss stocks - Factors to watch on July 29 ZURICH/GDANSK, July 29 (Reuters) - Here are some of the main factors that may affect Swiss stocks on Monday: COMPANY STATEMENTS ROCHE HOLDING ROG.S Roche plans to fast-track weight loss pill to compete with rivals, FT reports. ANALYSTS' VIEWS HOLCIM AG HOLN.S - Jefferies raises target price to CHF 85.5 from CHF 84 ECONOMY SNB data on Swiss sight deposits due at 0800 GMT.
R
Reuters - 2 weken geleden

Roche To Fast-Track Weight Loss Pill To Compete With Rivals - FT

BRIEF-Roche To Fast-Track Weight Loss Pill To Compete With Rivals - FT July 29 (Reuters) - ROCHE TO FAST-TRACK WEIGHT LOSS PILL TO COMPETE WITH RIVALS - FT Source text: tinyurl.com/28xkkxtn Further company coverage: ROG.S
R
Reuters - 2 weken geleden

Roche to fast-track weight loss pill to compete with rivals, FT reports

Roche to fast-track weight loss pill to compete with rivals, FT reports July 29 (Reuters) - Swiss pharmaceutical company Roche ROG.S plans to fast-track its anti-obesity drugs to challenge Eli Lilly LLY.N and Novo Nordisk NOVOb.CO after unveiling promising data for a weight-loss pill, the Financial Times reported on Monday. Thomas Schinecker, CEO o
R
Reuters - 3 weken geleden

European shares fall as earnings deluge disappoints

UPDATE 2-European shares fall as earnings deluge disappoints STOXX 600 down 0.7% Universal Music Group slumps as streaming growth disappoints Kering down after weak H2 forecast Besi tumbles as Q3 outlook disappoints Unilever gains after H1 profit beat Updated at 1600 GMT By Pranav Kashyap and Shashwat Chauhan July 25 (Reuters) - European shares closed lower on Thursday as a slate of downbeat earnings reports in several sectors including tech and luxury weighed, while a global run for safe haven
K
L
N
R
R
S
A
E
F
U
G
Reuters - 3 weken geleden

STOXX 600 drops to 12-week low as earnings fail to impress

LIVE MARKETS-STOXX 600 drops to 12-week low as earnings fail to impress STOXX 600 down 1.2% CAC 40 hits lowest since Jan UMG tumbles after results European semis weak Healthcare shines Wall St futures steady Welcome to the home for real-time coverage of markets brought to you by Reuters reporters. You can share your thoughts with us at markets.research@thomsonreuters.com STOXX 600 DROPS TO 12-WEEK LOW AS EARNINGS FAIL TO IMPRESS European equities are in the red on Thursday as the decline in glob
A
R
S
V
E
F
U
G

Voorwaarden

Populaire activa

Disclaimer: De entiteiten van de XM Group bieden diensten en toegang tot ons online handelsplatform op basis van uitsluitend-uitvoering, waardoor een persoon de beschikbare content op of via de website kan bekijken en/of gebruiken, zonder dat dit is bedoeld voor wijziging of uitbreiding. Dergelijk(e) toegang en gebruik vallen onder: (i) de algemene voorwaarden; (ii) risicowaarschuwingen; en de (iii) volledige disclaimer. Dergelijke content wordt daarom alleen aangeboden als algemene informatie. Wees u er daarnaast vooral van bewust dat de inhoud op ons online handelsplatform geen verzoek of aanbieding omvat om transacties op de financiële markten uit te voeren. Het beleggen op welke financiële markt dan ook vormt een aanzienlijk risico voor uw vermogen.

Alle materialen die op ons online handelsplatform worden gepubliceerd zijn bedoeld voor educatieve/informatieve doeleinden en omvatten geen – en moeten niet worden beschouwd als het bevatten van – financieel, vermogensbelastings- of handelsadvies en aanbevelingen, of een overzicht van onze handelsprijzen, of een aanbod of aanvraag van een transactie in financiële instrumenten of ongevraagde financiële promoties voor u.

Alle content van derden, alsmede content die is voorbereid door XM, zoals opinies, nieuws, onderzoeken, analyses, prijzen en andere informatie of koppelingen naar externe websites op deze website worden aangeboden op een 'zoals-ze-zijn'-basis, als algemene marktcommentaren, en vormen geen beleggingsadvies. Voor zover dat content wordt beschouwd als beleggingsonderzoek, moet u zich ervan bewust zijn en accepteren dat de content niet bedoeld was en niet is voorbereid in overeenstemming met de wettelijke vereisten die zijn opgesteld om de onafhankelijkheid van beleggingsonderzoek te bevorderen en als zodanig onder de geldende wetgeving en richtlijnen moet worden beschouwd als marketingcommunicatie. Zorg ervoor dat u onze Mededeling over niet-onafhankelijk beleggingsonderzoek en risicowaarschuwing in verband met de voorgaande informatie doorneemt en begrijpt; die kunt u hier lezen.

Risicowaarschuwing: Uw vermogen loopt risico. Hefboomproducten zijn mogelijk niet voor iedereen geschikt. Lees onze informatie over risico's.